Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. Theratechnologies Inc. was founded in 1993 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:TH
CUSIPN/A
Phone+1-514-3367800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-33.47%
Return on Equity-38.09%
Return on Assets-22.70%
Miscellaneous
EmployeesN/A
Outstanding Shares76,658,000
Market CapC$737.77 million
Theratechnologies (TSE:TH) Frequently Asked Questions
What is Theratechnologies' stock symbol?
Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."
How were Theratechnologies' earnings last quarter?
Theratechnologies Inc (TSE:TH) issued its quarterly earnings results on Thursday, July, 5th. The company reported ($0.03) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.03). The business had revenue of $12.33 million for the quarter, compared to analyst estimates of $13.40 million. Theratechnologies had a negative return on equity of 38.09% and a negative net margin of 33.47%. View Theratechnologies' Earnings History.
When is Theratechnologies' next earnings date?
What price target have analysts set for TH?
2 brokerages have issued 12 month price targets for Theratechnologies' shares. Their forecasts range from C$9.25 to C$15.00. On average, they expect Theratechnologies' stock price to reach C$13.25 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for Theratechnologies.
What is the consensus analysts' recommendation for Theratechnologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theratechnologies.
Who are some of Theratechnologies' key competitors?
Some companies that are related to Theratechnologies include BTG (BTG), Abcam (ABC), MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL) and MediGene (MDG1).
Who are Theratechnologies' key executives?
Theratechnologies' management team includes the folowing people:
- Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 60)
- Mr. Philippe Dubuc, Sr. VP & CFO (Age 51)
- Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 50)
- Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 55)
- Ms. Lyne Fortin, Sr. VP & Chief Commercial Officer (Age 58)
Has Theratechnologies been receiving favorable news coverage?
News headlines about TH stock have trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Theratechnologies earned a media and rumor sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the company an impact score of 46.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Theratechnologies.
How do I buy shares of Theratechnologies?
Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theratechnologies' stock price today?
One share of TH stock can currently be purchased for approximately C$9.60.
How big of a company is Theratechnologies?
Theratechnologies has a market capitalization of C$737.77 million.
How can I contact Theratechnologies?
Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.
MarketBeat Community Rating for Theratechnologies (TSE TH)
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe TH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days.
